Menu
Menu
The SOPHiA GENETICS network now includes the East Genomics laboratory in Cambridge. The lab delivers genetic and genomic testing for patients with cancer and rare diseases in the East of England.
The lab will use the SOPHiA DDM™ Platform for cancer profiling, including the analysis of solid tumour samples. All work will be conducted in-house, and will contribute to improving the understanding of complex cancers.
Learn more about our Solid Tumor Solutions: https://loom.ly/155gw_Q
🌍 We’re proud to highlight that Tyrolpath, the largest private pathology lab in western Austria, is the first lab in Austria to adopt MSK-IMPACT®-Flex powered with SOPHiA DDM™, marking a major milestone for precision oncology in the country.
With approximately 45,000 new cancer diagnoses reported each year, there is a strong need for comprehensive genomic profiling (CGP) to identify actionable mutations, especially as precision oncology becomes more central in clinical practice.
“I have met with the experts at Memorial Sloan Kettering Cancer Center before, and having the opportunity to utilize their assays in my own lab thanks to SOPHiA GENETICS is going to be a transformative step for cancer testing in Austria. Leveraging the power of the SOPHiA DDM™ Platform will help us advance precision oncology for our Austrian patients.” Said Peter Obrist, CEO, Tyrolpath.
Built on the proven backbone of MSK-IMPACT® combined with the cloud-based SOPHiA DDM™ Platform, MSK-IMPACT® Flex empowers laboratories to achieve flexible, cost-efficient insights into key solid tumor biomarkers based on individual patient cases.
🧬 At SOPHiA GENETICS, we believe in empowering labs to accelerate innovation. With this collaboration, we’re taking another step forward in bringing cutting-edge CGP testing to Austria.
Learn more about our comprehensive genomic profiling applications: https://www.sophiagenetics.com/sophia-ddm-for-genomics/solid-tumors/cgp/
We are thrilled to share that TomaLab, one of the largest genetic laboratories in Italy, has expanded their partnership with SOPHiA GENETICS, adding exome, solid tumor and hereditary cancer applications to gain insights across multiple cancers and inherited disorders.
By combining TomaLab’s deep expertise with our platform’s advanced analytics, they are now poised to deliver an even broader range of insights for the populations they serve.
At SOPHiA GENETICS, we believe that democratizing data-driven medicine begins with strong collaborations like this — ones that empower labs to go further, faster and smarter.
Learn more about our platform and the applications it offers: https://www.sophiagenetics.com/sophia-ddm/
Welcome to our global network Unilabs Netherlands!
Unilabs Netherlands is one of the country’s leading diagnostic healthcare providers, offering a comprehensive range of laboratory, imaging, pathology and specialized services through a large network of labs and sample‐collection points to make reliable diagnostics accessible to patients and providers.
They will leverage SOPHiA DDM™ to analyze inherited and rare disorders to find clarity for some of the most complex genetic cases. They join over 800 institutions who are harnessing the power of AI and data-driven medicine to advance precision care.
Learn more about our Inherited and Rare Disorder solutions: https://www.sophiagenetics.com/sophia-ddm-for-genomics/inherited-disorders/
🚀 We are proud to continue our expansion in the Middle East through our collaboration with National Reference Laboratory (NRL), a leader in pathology and one of the largest CAP-accredited laboratory networks in the region.
This partnership reflects a shared commitment to advancing data-driven cancer care and expanding access to genomic insights across the UAE.
As part of this collaboration, NRL has adopted MSK-IMPACT® powered with SOPHiA DDM™ — a decentralized, comprehensive genomic profiling solution co-developed with Memorial Sloan Kettering Cancer Center.
By integrating this cutting-edge application, NRL is expanding access to advanced, clinically relevant genomic insights across the UAE—enabling more informed decisions in cancer care through data-driven precision medicine.
🤝 We are honored to partner with NRL and look forward to the impact our collaboration will bring to data-driven medicine in the Middle East.
#PrecisionOncology #Genomics #UAEHealthcare #DataDrivenMedicine #Partnership #CancerCare
ROLLE, Switzerland - September 17, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced that it has joined NAIPO (National AI Initiative for Precision Oncology), a new national initiative aimed to develop a secure, Swiss-hosted infrastructure to enable AI-enhanced precision oncology across Switzerland.
According to the Global Cancer Observatory, cancer remains one of the country’s most pressing public health challenges, with nearly 58,000 new cases and close to 20,000 deaths recorded in 2022. Achieving fully personalized care remains challenging due to fragmented data and limited integration across institutions. A closer coordination across the national healthcare network will result in more effective and equitable treatments for patients.
NAIPO responds to this need with an integrated, AI-powered precision oncology platform to transform cancer care delivery. By applying advanced AI models at every stage of the patient journey, it aims to optimize diagnostics, personalize treatments, and support data-driven clinical decision-making.
“Building on lessons from previous efforts in precision oncology in Switzerland, our initiative targets the development of novel, clinically informed AI tools by seamlessly integrating a common data platform, continuously adapting robust models, and designing effective clinical interfaces and patient apps.” says Dorina Thanou, lead of the initiative at the EPFL AI Center.
Selected as a Flagship Initiative by Innosuisse, the Swiss Innovation Agency, NAIPO will unfold over four years under the leadership of the EPFL AI Center and ETH AI Center, uniting a large transdisciplinary team from a wide array of institutions including SOPHiA GENETICS, the Swiss Data Science Center (SDSC), the Swiss National Supercomputing Centre (CSCS), the Universities of Applied Sciences and Arts of Northwestern Switzerland, the Bern University of Applied Sciences, the Universities and University Hospitals of Basel, Bern, Geneva, and Zurich, Debiopharm, Roche, Switch, Tune Insight, as well as the regional hospitals of Aarau, Baden, Ticino, Luzern and Winterthur and the private clinics of Hirslanden and Swiss Medical Network. With an expected total cost of CHF 18.9 million, the project will receive approximately CHF 8.25 million in public funding from Innosuisse with the remaining amount coming from the implementation partners.
Transforming cancer research
NAIPO pioneers new AI approaches in cancer research and care, from clinical decision-support agents and large language models for records mining, to foundation models for treatment response prediction and privacy-preserving approaches. “Combined with high-throughput experimental models and patient avatars, these technologies will allow us to capture and model each patient’s uniqueness. The program will redefine AI’s role in medicine and strengthen Switzerland’s position as a leader in medical AI innovation” said Elisa Oricchio, director of the Swiss Institute of Experimental Cancer Research (ISREC) at EPFL
“Tailoring predictions and recommendations to individual patients is one of the most exciting aspects of NAIPO,” said Charlotte Bunne, professor at EPFL working on model development. “Our models will continuously learn from curated biomedical literature, as well as from individual biological and clinical data to identify potential new targets, biomarkers, and investigational drugs. Novel AI-driven insights will be integrated with clinically validated models and translated into decision-support systems.” Placing patients’ specific needs at the center of the initiative, dedicated solutions will be developed, such as a mobile app, to enhance communication and ensure patients remain actively informed and engaged throughout their care.
Deployment and long term vision
The program’s roadmap foresees clinical pilots at university and cantonal hospitals and private clinics, leading to an initial rollout at participating hospitals nationwide within four years. In addition to advancing cancer care, the infrastructure is intended to serve as a model for future applications in other disease domains.
“This initiative marks a transition toward a proactive model for precision oncology,” said Olivier Michielin, Head of Precision Oncology at Geneva University Hospitals (HUG) and Clinical Co-Coordinator of the project. “It reflects a commitment to ensuring that all patients, regardless of where they are treated within this network, benefit from the latest advances in AI-supported medicine.”
Secure, privacy-conscious collaboration is central to the initiative. Using modern data governance, the infrastructure will enable collective intelligence without centralizing sensitive health data. “We’re creating a secure and federated system that allows collaboration across institutions without compromising privacy,” said Nora Toussaint, Lead Health & Biomedical at the Swiss Data Science Center (SDSC). “Trust and transparency will be built into the design.”
“NAIPO is exactly what clinical oncology needs today. We are able to produce much more data than a couple of years ago, but we often don't know how to integrate this in actual patient care. NAIPO is instrumental to close this gap.” Says Andreas Wicki, oncology professor at the University of Zurich and Clinical Co-Coordinator of the project.
NAIPO’s long-term vision includes reducing disparities in access, accelerating the discovery of new biomarkers and treatments, and supporting sustainable innovation across the Swiss healthcare system. Milestones and key results will be shared as the project progresses.
BOSTON, MA and ROLLE, Switzerland, September 5, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has announced a significant new collaboration with Jessa Ziekenhuis in Hasselt, Belgium. The institutions will partner to bring cutting edge genomic testing and oncology research to cancer patients across Belgium.
Jessa Ziekenhuis, one of Belgium’s largest healthcare institutions, serves a population of over 530,000 and processes more than 3,000 oncology DNA and RNA samples annually. Through this collaboration, the hospital will adopt SOPHiA DDM™ across its pathology operations to unify its next-generation sequencing (NGS) workflows under a single platform. This full standardization, covering universal library preparation, unified automated protocols, and a fully integrated workflow, will ensure efficiency, harmonization, and compliance with national ComPerMed guidelines, while enabling more effective use of sequencing resources.
The hospital will implement six SOPHiA GENETICS applications tailored to its testing needs in solid tumors, hematologic malignancies, and liquid biopsy analysis, enhancing both clinical decision-making and research capabilities.
The SOPHiA GENETICS solution combines a cloud-based platform with embedded automation and advanced analysis tools, fully integrated with Jessa Ziekenhuis’s Laboratory Information Management System (LIMS). This ensures seamless data flow, consistency across the workflow, and significantly streamlined operations.
By unifying its entire pathology NGS operation under this single workflow, Jessa Ziekenhuis expects to cut hands-on time by 30–50%, reduce overall costs by up to 25%, and accelerate testing turnaround times. This harmonized approach also enables more efficient use of sequencers, record implementation-to-accreditation timelines, and better scalability.
Furthermore, the SOPHiA DDM™ Dispatch feature will enable Jessa Ziekenhuis to seamlessly share a NovaSeq sequencer with AZ Delta in Roeselare, Belgium. Jessa and AZ Delta jointly and equally invested in the NovaSeq, and on this foundation the two hospitals established the Bridge Consortium to provide sequencing services together. This collaborative network improves turnaround times, optimizes use of sequencing capacity, and strengthens knowledge sharing.
“At Jessa Ziekenhuis, we are strongly committed to innovation in order to provide our patients with access to the most advanced oncological care. Through our collaboration with SOPHiA GENETICS, we can fully harmonize and accelerate our NGS workflows. This step enables us to generate molecular insights faster and more accurately, which benefits both clinical decision-making and our research projects. Ultimately, this is an important investment in personalized medicine and in the quality of care for Belgian patients with cancer,” said Dr. Brigitte Maes, Clinical Pathologist at Laboratory for Molecular Diagnostics at Jessa Ziekenhuis.
“Our collaboration with Jessa Ziekenhuis exemplifies how SOPHiA GENETICS can support leading institutions in scaling their genomics capabilities while ensuring the highest possible quality and efficiency,” said Kevin Puylaert, Managing Director of EMEA, SOPHiA GENETICS. “By delivering a fully automated, cloud-native solution tailored to their oncology needs, we’re empowering Jessa Ziekenhuis to unify workflows, accelerate insights, and elevate patient care across Belgium.”
With this agreement, SOPHiA GENETICS further strengthens its footprint across European hospital networks, bringing scalable, decentralized, data-driven precision medicine to institutions advancing patient care through cutting-edge genomics. Learn more by connecting with SOPHiA GENETICS at the European Congress of Pathology in Vienna, Austria, September 6-9, 2025. For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
Centre Hospitalier du Pays d’Aix, a major hospital serving the Provence region in southern France, has joined the SOPHiA GENETICS global network to expand its precision oncology capabilities.
The institution is now leveraging both the SOPHiA DDM™ Myeloid Solution and Solid Tumor Targeted Applications, unlocking new layers of insight for the diagnosis and treatment of hematologic malignancies and solid tumors. These multimodal, AI-powered applications help clinicians detect actionable biomarkers more accurately, efficiently, and confidently.
With over 800 hospitals worldwide already using SOPHiA GENETICS technology, Centre Hospitalier du Pays d’Aix is now part of a growing movement to make data-driven medicine the global standard.
Explore the solutions:
We’re excited to announce that Hospital Arnau de Vilanova de Valencia—one of Spain’s premier academic health science centers—has expanded its collaboration with SOPHiA GENETICS.
The team is now harnessing the capabilities of the SOPHiA DDM™ Community Myeloid Solution—our DNA-only, multimodal-ready application—to support deeper, more actionable insights in the analysis of myeloid malignancies.
This expanded partnership reinforces Hospital Arnau de Vilanova de Valencia’s dedication to driving innovation in hematologic cancer research, joining a growing global community of 800+ institutions using SOPHiA DDM™ to streamline complex variant analysis."
Filmed as part of the Swiss Biotech Day on May 5th 2025.
An engaging panel discussion on the transformative role of AI-powered technology in building scalable, high-performance healthcare solutions. Discover how collaboration drives innovation and advances precision medicine.
Discussion summary:
Artificial intelligence and big data are revolutionizing biotech and healthcare, driving breakthroughs in precision medicine, clinical decision-making, and drug discovery. This panel showcases how adaptive our autonomous AI models enhance decision-making and improve industry performance and productiivity. Additionally, the discussion will emphasize the importance of robust AI infrastructure in creating scalable, high-performance healthcare solutions, while also highlighting the necessity of strong, high-quality data for accurate AI concepts.
Experts will delve into advancements in clinical development productivity, patient data analytics, AI-powered diagnostics, and the agent-based concepts, while also highlighting local initiatives designed to foster collaboration and innovation in healthcare AI.
Moderator:
Panellists:
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.